NCT07465224
A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus
StatusActive, Not Recruiting
PhasePhase 2
SponsorAlnylam Pharmaceuticals
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 4 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Study completion pushed from May 28, 2027 to Jul 30, 2027
- Site details revised
- Notable Eligibility criteria expanded, about 6 words
- Secondary endpoints: details revised at 1 of 5 entries
- Notable Enrollment reduced: 40 → 24 participants
- Eligibility criteria expanded, about 10 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline in M-value
Timeframe: Baseline up to Month 3
Secondary (5)
Frequency of Adverse Events (AEs)
Change from Baseline in M/I
Change from Baseline in M-value
Change from Baseline in Endogenous Glucose Production (EGP)
Change from Baseline in Hemoglobin A1c (HbA1c)
Arms and interventions
ALN-4324Experimental
Participants will be administered a single dose of ALN-4324.
PlaceboPlacebo comparator
Participants will be administered a single dose of placebo.
Drugs: ALN-4324, Placebo
Sites
1 site in 1 country
- Clinical Trial SiteChula Vista, California, United States